Projects per year
Personal profile
Biography
Professor Jian Li (PhD 2002) is an elected Fellow of the American Academy of Microbiology and Head of the Antimicrobial Systems Pharmacology Laboratory at the Biomedicine Discovery Institute, Monash University. He is a Web of Science Highly Cited Researcher in Pharmacology & Toxicology (2015 - 2017, 2022). Dr Li has an internationally recognised track record in the pharmacology of polymyxins and the discovery of novel, safer antimicrobial peptides. He has 424 publications (including 328 on polymyxins alone) with 26,721 citations and an h-index of 79. His team has developed a novel lipopeptide drug QPX9003 from concept into the clinic to target MDR Gram-negative pathogens (NIH/NIAID). Phase-I clinical trials are underway in the USA and clinical data are featured in several presentations at the ID Week Meeting in Washington, DC (2022). The majority of modern polymyxin pharmacology data are reported by his group. His research has led to the first dosing guidelines of polymyxins which have been adopted worldwide and have significantly improved clinical practice. Dr Li's research is funded by the NIH, NHMRC, ARC, pharmaceutical companies and other grant bodies. Dr Li is Editor-in-Chief of The International Journal of Antimicrobial Agents and an Associate Editor of Frontiers in Microbiology. He is an invited reviewer for 190 international journals and grant/fellowship applications for the Australian National Health and Medical Research Council (NHMRC), Australian Research Council (ARC) and 26 international funding bodies (e.g. NIH/NIAID). Dr Li has received numerous awards, including Australian Leadership Award (2013), Australian National Health and Medical Research Council’s Ten of the Best Research Projects (2014) and Australian Academy of Science Jacques Miller Medal (2017).
Monash teaching commitment
Supervisor of PhD, Masters and Honours students
Research interests
Antibiotics are a cornerstone of modern medicine and over the last century have significantly decreased mortality worldwide. Unfortunately, resistance to these ‘magic bullets’ has become one of the greatest threats to human health that the world faces, now and in the coming decades. If proactive solutions are not found to prevent widespread antibiotic resistance, it is estimated that by 2050 ~10 million people per year will die of infections. The World Health Organization (WHO) has urged all government sectors and society to act on antimicrobial resistance (AMR). In 2017, multidrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii were identified by WHO as the highest priority pathogens, which require urgent attention for the discovery of novel antibiotics. Over the last decade, ‘old’ polymyxins are increasingly used as the last defence against these Gram-negative ‘superbugs’ and unfortunately, resistance to polymyxins has been increasingly reported. As no new antibiotics will be available for Gram-negative ‘superbugs’ in the near future, it is crucial to optimise the clinical use of current antibiotics and develop novel therapies.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Research area keywords
- Antimicrobial Resistance
- Drug Discovery
- Antimicrobial Pharmacology
- Systems Pharmacology
- Computational Biology
- Bioinformatics
- Polymyxin
- Colistin
- Pharmacodynamics
- Pharmacokinetics
- Acinetobacter baumannii
- Klebsiella pneumoniae
- Pseudomonas aeruginosa
Network
-
High-Precision Mass Spectrometry Imaging Facility
Voelcker, N., Tuck, K., McConville, M., Li, J., Loessner, D., Pigram, P. J., van Oppen, M. J. H., Winkler, D., Hartland, E., Velkov, T., Stewart, A., Schittenhelm, R., Williamson, N. A., Rudd, D. & Baybrook, C.
Australian Research Council (ARC)
17/03/23 → 16/03/24
Project: Research
-
Revolutionising phage therapy: Integration of modern pharmacokinetic-pharmacodynamic modelling and systems pharmacology
Nang, S., Li, J., Wicha, S. & Tikiso, T.
Monash University – Internal University Contribution
1/01/22 → 31/12/23
Project: Research
-
Combating superbug infections using systems pharmacology and computer science
Li, J., Zhao, J., Schreiber, F., Jaeger-Honz, S. & Garkov, D.
1/01/22 → 31/12/23
Project: Research
-
Pathogenic membranes as therapeutic drug targets
Aguilar, M., Reid, G., Separovic, F., Yarovsky, I., Li, J. & Drummer, H.
1/01/22 → 31/12/25
Project: Research
-
Towards the Translation of Synergistic Phage-Polymyxin Combination Therapy against Pandrug-resistant Klebsiella pneumoniae: A Systems Approach
Li, J., Barr, J., Lin, W., Rao, G. & Schooley, R. T.
16/08/21 → 31/07/23
Project: Research
-
Critical Role of Position 10 Residue in the Polymyxin Antimicrobial Activity
Patil, N. A., Ma, W., Jiang, X., He, X., Yu, H. H., Wickremasinghe, H., Wang, J., Thompson, P. E., Velkov, T., Roberts, K. D. & Li, J., 6 Feb 2023, In: Journal of Medicinal Chemistry. 66, 4, p. 2865–2876 12 p.Research output: Contribution to journal › Article › Research › peer-review
-
Multi-modality data-driven analysis of diagnosis and treatment of psoriatic arthritis
Xu, J., Ou, J., Li, C., Zhu, Z., Li, J., Zhang, H., Chen, J., Yi, B., Zhu, W., Zhang, W., Zhang, G., Gao, Q., Kuang, Y., Song, J., Chen, X. & Liu, H., Dec 2023, In: npj Digital Medicine. 6, 1, 11 p., 13.Research output: Contribution to journal › Article › Research › peer-review
Open Access -
An Efficient Approach for the Design and Synthesis of Antimicrobial Peptide-Peptide Nucleic Acid Conjugates
Patil, N. A., Thombare, V. J., Li, R., He, X., Lu, J., Yu, H. H., Wickremasinghe, H., Pamulapati, K., Azad, M. A. K., Velkov, T., Roberts, K. D. & Li, J., 15 Mar 2022, In: Frontiers in Chemistry. 10, 10 p., 843163.Research output: Contribution to journal › Article › Research › peer-review
Open Access3 Citations (Scopus) -
An Intelligent Strategy with All-Atom Molecular Dynamics Simulations for the Design of Lipopeptides against Multidrug-Resistant Pseudomonas aeruginosa
Jiang, X., Han, M., Tran, K., Patil, N. A., Ma, W., Roberts, K. D., Xiao, M., Sommer, B., Schreiber, F., Wang, L., Velkov, T. & Li, J., 28 Jul 2022, In: Journal of Medicinal Chemistry. 65, 14, p. 10001-10013 13 p.Research output: Contribution to journal › Article › Research › peer-review
2 Citations (Scopus) -
A polytherapy based approach to combat antimicrobial resistance using cubosomes
Lai, X., Han, M-L., Ding, Y., Chow, S. H., Le Brun, A. P., Wu, C-M., Bergen, P. J., Jiang, J., Hsu, H-Y., Muir, B. W., White, J., Song, J., Li, J. & Shen, H-H., Dec 2022, In: Nature Communications. 13, 1, 12 p., 343.Research output: Contribution to journal › Article › Research › peer-review
Open Access13 Citations (Scopus)
Activities
- 1 Submissions to industry or govt committees, commissions and inquiries
-
Drug Delivery, Disposition and Dynamics
Jian Li (Member)
9 Nov 2011 → 9 Sep 2099Activity: External Academic Engagement › Submissions to industry or govt committees, commissions and inquiries
Press/Media
-
AI tool to boost genomic data analysis
Jiangning Song, Roger Daly & Jian Li
25/04/19
1 Media contribution
Press/Media: Research
-
Genome scale model of a superbug
Trevor Lithgow, Jian Li & Jiangning Song
16/03/18 → 30/03/18
2 Media contributions
Press/Media: Research
-
A$9.8 million fight against superbugs
Jian Li, William Neil Charman, Jiangning Song, Anthony Wayne Purcell, Paul John Hertzog, Darren John Creek, Roger Leigh Nation, Jurgen Bullita & John Dallas Boyce
24/04/14
1 Media contribution
Press/Media: Public Engagement Activities